Logo image of EWL.DE

EDWARDS LIFESCIENCES CORP (EWL.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:EWL - US28176E1082 - Common Stock

71.45 EUR
-0.72 (-1%)
Last: 12/12/2025, 7:00:00 PM

EWL.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap41.46B
Revenue(TTM)5.88B
Net Income(TTM)1.37B
Shares580.30M
Float573.15M
52 Week High76.02
52 Week Low59.3
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)2.19
PE32.63
Fwd PE28.5
Earnings (Next)02-09 2026-02-09/amc
IPO2000-03-27
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


EWL.DE short term performance overview.The bars show the price performance of EWL.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5

EWL.DE long term performance overview.The bars show the price performance of EWL.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 1 2 3

The current stock price of EWL.DE is 71.45 EUR. In the past month the price decreased by -2.72%. In the past year, price increased by 1.59%.

EDWARDS LIFESCIENCES CORP / EWL Daily stock chart

EWL.DE Competitors/Peers

The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
2M6.DE MEDTRONIC PLC 17.7 108.95B
SHL.DE SIEMENS HEALTHINEERS AG 18.67 50.32B
PHIA.AS KONINKLIJKE PHILIPS NV 15.26 21.74B
PHI1.DE KONINKLIJKE PHILIPS NV 15.32 21.84B
BIM.PA BIOMERIEUX 27.75 12.68B
OBCK.DE OTTOBOCK SE & CO KGAA 148.51 4.47B
AFX.DE CARL ZEISS MEDITEC AG - BR 23.51 3.60B
DIA.MI DIASORIN SPA 18.92 3.50B
DRW3.DE DRAEGERWERK AG - PREF 10.54 1.28B
DRW8.DE DRAEGERWERK AG 9.21 1.11B
ELN.MI EL.EN. SPA 21.23 1.09B
EUZ.DE ECKERT & ZIEGLER SE 23.2 957.88M

About EWL.DE

Company Profile

EWL logo image Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

Company Info

EDWARDS LIFESCIENCES CORP

One Edwards Way

Irvine CALIFORNIA US

Employees: 15800

EWL Company Website

EWL Investor Relations

Phone: 19492502500

EDWARDS LIFESCIENCES CORP / EWL.DE FAQ

Can you describe the business of EDWARDS LIFESCIENCES CORP?

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.


Can you provide the latest stock price for EDWARDS LIFESCIENCES CORP?

The current stock price of EWL.DE is 71.45 EUR. The price decreased by -1% in the last trading session.


Does EWL stock pay dividends?

EWL.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of EWL stock?

EWL.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What sector and industry does EDWARDS LIFESCIENCES CORP belong to?

EDWARDS LIFESCIENCES CORP (EWL.DE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


What is the market capitalization of EWL stock?

EDWARDS LIFESCIENCES CORP (EWL.DE) has a market capitalization of 41.46B EUR. This makes EWL.DE a Large Cap stock.


Can you provide the ownership details for EWL stock?

You can find the ownership structure of EDWARDS LIFESCIENCES CORP (EWL.DE) on the Ownership tab.


EWL.DE Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to EWL.DE. When comparing the yearly performance of all stocks, EWL.DE turns out to be only a medium performer in the overall market: it outperformed 60.72% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

EWL.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to EWL.DE. EWL.DE gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EWL.DE Financial Highlights

Over the last trailing twelve months EWL.DE reported a non-GAAP Earnings per Share(EPS) of 2.19. The EPS decreased by -3.75% compared to the year before.


Industry RankSector Rank
PM (TTM) 23.25%
ROA 10.31%
ROE 13.4%
Debt/Equity 0.06
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%14.67%
EPS 1Y (TTM)-3.75%
Revenue 1Y (TTM)4.67%

EWL.DE Forecast & Estimates

42 analysts have analysed EWL.DE and the average price target is 81.68 EUR. This implies a price increase of 14.32% is expected in the next year compared to the current price of 71.45.

For the next year, analysts expect an EPS growth of 1.44% and a revenue growth 4.59% for EWL.DE


Analysts
Analysts79.05
Price Target81.68 (14.32%)
EPS Next Y1.44%
Revenue Next Year4.59%

EWL.DE Ownership

Ownership
Inst Owners89.97%
Ins Owners0.11%
Short Float %N/A
Short RatioN/A